The Adaptive COVID-19 Treatment Trial (ACTT)

NIH RePORTER · NIH · N01 · $18,166,213 · view on reporter.nih.gov ↗

Abstract

To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.

Key facts

NIH application ID: 10272623
Project number: 75N91019D00024-0-759102000010-2
Recipient: LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator: BETH BASELER
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $18,166,213
Award type: —
Project period: 2020-04-03 → 2025-04-02